Reactivation After Chimeric Antigen Receptor T-Cell Therapy

Overview

Journal Open Forum Infect Dis

Specialty Infectious Diseases

Date 2024 Jan 24

PMID 38264096

Authors

Bayan Alahmdi

Avneet Kaur

Samantha E Jacobs

Timothy Sullivan

Maya Barghash

Sarah Taimur

Affiliations

Soon will be listed here.

Abstract

https://tidbitapp.io/tidbits/trypanosoma-cruzi-reactivation-post-chimeric-antigen-receptor-t-cell-therapy/update.

References

Bern C, Montgomery S . An estimate of the burden of Chagas disease in the United States. Clin Infect Dis. 2009; 49(5):e52-4. DOI: 10.1086/605091. View

Pinazo M, Miranda B, Rodriguez-Villar C, Altclas J, Brunet Serra M, Canas Garcia-Otero E . Recommendations for management of Chagas disease in organ and hematopoietic tissue transplantation programs in nonendemic areas. Transplant Rev (Orlando). 2011; 25(3):91-101. DOI: 10.1016/j.trre.2010.12.002. View

Kambhampati S, Sheng Y, Huang C, Bylsma S, Lo M, Kennedy V . Infectious complications in patients with relapsed refractory multiple myeloma after BCMA CAR T-cell therapy. Blood Adv. 2021; 6(7):2045-2054. PMC: 9006279. DOI: 10.1182/bloodadvances.2020004079. View

Kohl S, Pickering L, Frankel L, YAEGER R . Reactivation of Chagas' disease during therapy of acute lymphocytic leukemia. Cancer. 1982; 50(5):827-8. DOI: 10.1002/1097-0142(19820901)50:5<827::aid-cncr2820500503>3.0.co;2-#. View

Qvarnstrom Y, Schijman A, Veron V, Aznar C, Steurer F, da Silva A . Sensitive and specific detection of Trypanosoma cruzi DNA in clinical specimens using a multi-target real-time PCR approach. PLoS Negl Trop Dis. 2012; 6(7):e1689. PMC: 3389027. DOI: 10.1371/journal.pntd.0001689. View

Czech M, Nayak A, Subramanian K, Suarez J, Ferguson J, Jacobson K . Reactivation of Chagas Disease in a Patient With an Autoimmune Rheumatic Disease: Case Report and Review of the Literature. Open Forum Infect Dis. 2021; 8(2):ofaa642. PMC: 7863873. DOI: 10.1093/ofid/ofaa642. View

Hill J, Li D, Hay K, Green M, Cherian S, Chen X . Infectious complications of CD19-targeted chimeric antigen receptor-modified T-cell immunotherapy. Blood. 2017; 131(1):121-130. PMC: 5755046. DOI: 10.1182/blood-2017-07-793760. View

Guiang K, Cantey P, Montgomery S, Ailawadhi S, Qvarnstrom Y, Price T . Reactivation of Chagas disease in a bone marrow transplant patient: case report and review of screening and management. Transpl Infect Dis. 2013; 15(6):E264-7. PMC: 10166063. DOI: 10.1111/tid.12157. View

Gray E, La Hoz R, Green J, Vikram H, Benedict T, Rivera H . Reactivation of Chagas disease among heart transplant recipients in the United States, 2012-2016. Transpl Infect Dis. 2018; 20(6):e12996. PMC: 6289649. DOI: 10.1111/tid.12996. View

10.

Morillo C, Marin-Neto J, Avezum A, Sosa-Estani S, Rassi Jr A, Rosas F . Randomized Trial of Benznidazole for Chronic Chagas' Cardiomyopathy. N Engl J Med. 2015; 373(14):1295-306. DOI: 10.1056/NEJMoa1507574. View

11.

Gea-Banacloche J . Infectious complications of chimeric antigen receptor (CAR) T-cell therapies. Semin Hematol. 2023; 60(1):52-58. PMC: 10119490. DOI: 10.1053/j.seminhematol.2023.02.003. View

12.

Fabiani S, Fortunato S, Petrini M, Bruschi F . Allogeneic hematopoietic stem cell transplant recipients and parasitic diseases: A review of the literature of clinical cases and perspectives to screen and follow-up active and latent chronic infections. Transpl Infect Dis. 2017; 19(2). DOI: 10.1111/tid.12669. View

13.

Wudhikarn K, Perales M . Infectious complications, immune reconstitution, and infection prophylaxis after CD19 chimeric antigen receptor T-cell therapy. Bone Marrow Transplant. 2022; 57(10):1477-1488. PMC: 9285870. DOI: 10.1038/s41409-022-01756-w. View

14.

Tomblyn M, Chiller T, Einsele H, Gress R, Sepkowitz K, Storek J . Guidelines for preventing infectious complications among hematopoietic cell transplantation recipients: a global perspective. Biol Blood Marrow Transplant. 2009; 15(10):1143-238. PMC: 3103296. DOI: 10.1016/j.bbmt.2009.06.019. View

15.

Torrico F, Gascon J, Barreira F, Blum B, Almeida I, Alonso-Vega C . New regimens of benznidazole monotherapy and in combination with fosravuconazole for treatment of Chagas disease (BENDITA): a phase 2, double-blind, randomised trial. Lancet Infect Dis. 2021; 21(8):1129-1140. DOI: 10.1016/S1473-3099(20)30844-6. View

16.

Kampouri E, Little J, Rejeski K, Manuel O, Hammond S, Hill J . Infections after chimeric antigen receptor (CAR)-T-cell therapy for hematologic malignancies. Transpl Infect Dis. 2023; 25 Suppl 1:e14157. DOI: 10.1111/tid.14157. View

17.

La Hoz R, Morris M . Tissue and blood protozoa including toxoplasmosis, Chagas disease, leishmaniasis, Babesia, Acanthamoeba, Balamuthia, and Naegleria in solid organ transplant recipients- Guidelines from the American Society of Transplantation Infectious Diseases.... Clin Transplant. 2019; 33(9):e13546. DOI: 10.1111/ctr.13546. View

18.

Rezende R, Lescano M, Ramalho L, Figueiredo J, Dantas R, Garzella Meneghelli U . Reactivation of Chagas' disease in a patient with non-Hodgkin's lymphoma: gastric, oesophageal and laryngeal involvement. Trans R Soc Trop Med Hyg. 2005; 100(1):74-8. DOI: 10.1016/j.trstmh.2005.07.005. View

19.

Morillo C, Waskin H, Sosa-Estani S, Del Carmen Bangher M, Cuneo C, Milesi R . Benznidazole and Posaconazole in Eliminating Parasites in Asymptomatic T. Cruzi Carriers: The STOP-CHAGAS Trial. J Am Coll Cardiol. 2017; 69(8):939-947. DOI: 10.1016/j.jacc.2016.12.023. View

20.

Boscardin S, Torrecilhas A, Manarin R, Revelli S, Rey E, Tonelli R . Chagas' disease: an update on immune mechanisms and therapeutic strategies. J Cell Mol Med. 2010; 14(6B):1373-84. PMC: 3829005. DOI: 10.1111/j.1582-4934.2010.01007.x. View